Diagnosing invasive fungal infections on DNA extracted from serum or plasma of immunocompromised patients with a suspected invasive pulmonary fungal infection

Diagnosing invasive fungal infections on DNA extracted from serum or plasma of immunocompromised patients with a suspected invasive pulmonary fungal infection - Aspergillus Resistance PCR Optimalization study (ARPOS-study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50191

Enrollment

300

Registered

2017-08-30

Start date

2018-06-28

Completion date

Unknown

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

invasive aspergillosis invasive fungal infections

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: *18 years or older *Lung CT showes lesions that fullfill the EORTC/MSG radiological criterium of possible invasive fungal infection. *A bronchoalveolar lavage is planned or has been performed

Exclusion criteria

Exclusion criteria: * Unable or unwilling to provide informed consent

Design outcomes

Primary

Measure	Time frame
All patients will be classified as proven, probable or possible, undetermined or no invasive pulmonary fungal infection according to the EORTC/MSG criteria. From the patients with probable or proven invasive aspergillosis, the number and percentages of patients samples producing a result by two different PCRs.	—

Countries

Netherlands

Outcome results